Research subject advocacy: Program implementation and evaluation at clinical and translational science award centers

Academic Medicine

Volumn 87, Issue 9, 2012, Pages 1228-1236

  Kost, Rhonda G ^a,b   Reider, Carson ^c   Stephens, Julie ^c   Schuff, Kathryn G ^d  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Regulatory Knowledge Key Function Committee and Research Subject Advocacy   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866021070     PISSN: 10402446     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACM.0b013e3182628afa     Document Type: Article

References (17)

1. National Center for Research Resources. Research Subject Advocates. NCRR Division for Clinical Research Resources: Guidelines of the General Clinical Research Centers Program 2005. http://www.ncrr. nih.gov/clinical-research- resources/GCRC-archives/GCRC-Guidelines-September2005.pdf. Accessed May 28, 2012.
2. Neill KM. Research subject advocate: A new protector of research participants. Account Res. 2003;10:159-174.
3. O'Lonergan T. Creative solutions: Research subject advocates: Increase in reports of human subject protection deficiencies bring scrutiny as well as more efforts at education and support. Prot Hum Subj. Spring 2003: 10-11.
4. Clinical and Translational Science Awards. Regulatory Knowledge-Research Subject Advocacy. https://www.ctsacentral. org/committee/regulatory- knowledgeresearch-subject-advocacy. Accessed May 14, 2012.
5. Society of Research Subject Advocates Web site. http://www.srsa.us. Accessed May 14, 2012.
6. Bramstedt KA. Research subject advocates: To whom are they loyal? Clin Invest Med. 2003;26:64-69.
7. Carroll PR; Prostate Cancer Advocates. The impact of patient advocacy: The University of California-San Francisco experience. J Urol. 2004;172(5 pt 2):S58-S61.
8. Easa D, Kim K, Kato K, et al. The research subject advocate at the University of Hawai'i Clinical Research Center: An added resource for protection of human subjects. Hawaii Med J. 2006;65:50-52.
9. Martinez RA. Role of research subject advocates in the development of data safety and monitoring plans. J Investig Med. 2004;52:464-469.
10. Stroup S, Appelbaum P. The subject advocate: Protecting the interests of participants with fluctuating decisionmaking capacity. IRB. 2003;25:9-11.
11. Silber TJ. Protection of children in research: Beyond pediatric risk levels: The emergence of the research subject advocate. J Clin Ethics. 2010;21:221-223.
12. Rhonda G. Kost, Chair, Research Subject Advocacy taskforce, Regulatory Knowledge Committee. Personal communication with Meryl Sufian, Evaluation Committee, February 13, 2012.
13. Bierer B, Winkler S. Alternative IRB approvals for multisite trials, Harvard reliance agreement. Paper presented at: 4th Annual CTSA Clinical Research Management Workshop; 2011; Bethesda, Md.
14. Winkler S. Making sausages from silos. Paper presented at: CTSA Regulatory Knowledge Key Function Committee Face to Face Meeting; 2011; Bethesda, Md.
15. Kost RG, Lee LM, Yessis J, Coller BS, Henderson DK; Research Participant Perception Survey Focus Group Subcommittee. Assessing research participants' perceptions of their clinical research experiences. Clin Transl Sci. 2011;4:403-413.
16. Institute for Healthcare Improvement. Failure Modes and Effects Analysis Tool. http://app.ihi.org/Workspace/tools/fmea/. Accessed May 14, 2012.
17. Cody RJ. Anticipating risk for human subjects participating in clinical research: Application of failure mode and effects analysis. Cancer Invest. 2006;24:209-214.